{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T04:31:43Z","timestamp":1792816303100,"version":"4.5.0"},"reference-count":23,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T00:00:00Z","timestamp":1554249600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2019,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>To examine the potential role of Medical Information Database Network (MID\u2010NET<jats:sup>\u00ae<\/jats:sup>), a newly established Japanese medical information database network, in postmarketing drug safety assessments through the characterization of its advantages and limitations in five pilot studies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The pilot studies were designed to address three major objectives in postmarketing drug safety assessments, ie, the examination of actual drug utilization, the impact of safety\u2010related regulatory actions, and drug\u2010associated risks. The five studies were conducted on the following topics: (a) utilization of codeine\u2010containing products and its relationship with respiratory depression, (b) impact of a Dear Healthcare Professional letter on hypocalcemia incidence associated with denosumab (Ranmark<jats:sup>\u00ae<\/jats:sup>) use, (c) risk of acute myocardial infarction associated with antidiabetic drug use, (d) risk of glucose metabolism disorders associated with atypical antipsychotic drug use, and (e) prospective monitoring of abnormal laboratory test results during new drug prescriptions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The pilot studies were successfully conducted and demonstrated the value of MID\u2010NET<jats:sup>\u00ae<\/jats:sup> in postmarketing drug safety assessments. In particular, the ability to utilize laboratory test results as objective clinical indicators is a major advantage of this database. Potential limitations include a relatively small sample size and a lack of patient\u2010level data linkages among hospitals.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>MID\u2010NET<jats:sup>\u00ae<\/jats:sup> was confirmed to be a valuable database for postmarketing drug safety assessments. The use of laboratory test results to define clinical outcomes may allow more objective and accurate analyses to be conducted. These studies furthered our understanding of the characteristics of MID\u2010NET<jats:sup>\u00ae<\/jats:sup>, including its advantages and limitations.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.4777","type":"journal-article","created":{"date-parts":[[2019,4,4]],"date-time":"2019-04-04T06:34:27Z","timestamp":1554359667000},"page":"601-608","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["The utilization and challenges of Japan's MID\u2010NET<sup>\u00ae<\/sup> medical information database network in postmarketing drug safety assessments: A summary of pilot pharmacoepidemiological studies"],"prefix":"10.1002","volume":"28","author":[{"given":"Kaori","family":"Yamada","sequence":"first","affiliation":[{"name":"Office of Medical Informatics and Epidemiology Pharmaceuticals and Medical Devices Agency  Tokyo 100\u20100013 Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maori","family":"Itoh","sequence":"additional","affiliation":[{"name":"Office of Medical Informatics and Epidemiology Pharmaceuticals and Medical Devices Agency  Tokyo 100\u20100013 Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Fujimura","sequence":"additional","affiliation":[{"name":"Head Office Tokushukai Information System Incorporated  Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michio","family":"Kimura","sequence":"additional","affiliation":[{"name":"Department of Medical Informatics Hamamatsu University Hospital  Shizuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Murata","sequence":"additional","affiliation":[{"name":"Department of Radiology Kitasato University Hospital  Kanagawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Nakashima","sequence":"additional","affiliation":[{"name":"Department of Advanced Information Technology Kyushu University Hospital  Fukuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaharu","family":"Nakayama","sequence":"additional","affiliation":[{"name":"Medical Informatics Tohoku University Graduate School of Medicine  Miyagi Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Ohe","sequence":"additional","affiliation":[{"name":"Department of Healthcare Information Management The University of Tokyo Hospital  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takao","family":"Orii","sequence":"additional","affiliation":[{"name":"Department of Pharmacy NTT Medical Center Tokyo  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eizaburo","family":"Sueoka","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine Saga University Hospital  Saga Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Medical Informatics Chiba University Hospital  Chiba Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideto","family":"Yokoi","sequence":"additional","affiliation":[{"name":"Department of Medical Informatics Kagawa University Hospital  Kagawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1302-9430","authenticated-orcid":false,"given":"Chieko","family":"Ishiguro","sequence":"additional","affiliation":[{"name":"Office of Medical Informatics and Epidemiology Pharmaceuticals and Medical Devices Agency  Tokyo 100\u20100013 Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0430-9887","authenticated-orcid":false,"given":"Yoshiaki","family":"Uyama","sequence":"additional","affiliation":[{"name":"Office of Medical Informatics and Epidemiology Pharmaceuticals and Medical Devices Agency  Tokyo 100\u20100013 Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of MID\u2010NET project group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,4,3]]},"reference":[{"key":"e_1_2_14_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsb1609216"},{"key":"e_1_2_14_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.2311"},{"key":"e_1_2_14_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.2209"},{"key":"e_1_2_14_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4032"},{"key":"e_1_2_14_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.320"},{"key":"e_1_2_14_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4381"},{"key":"e_1_2_14_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12328-014-0474-6"},{"key":"e_1_2_14_9_1","doi-asserted-by":"crossref","unstructured":"YamaguchiM InomataS HaradaA et al.Establishment of the MID\u2010NET\u00aemedical information database network as a reliable and valuable database for drug safety assessments in Japan.2019: submitted.","DOI":"10.1002\/pds.4879"},{"key":"e_1_2_14_10_1","unstructured":"Pharmaceuticals and Medical Devices Agency Establishment of Regulatory Science Center and formal launch of MID\u2010NET\u00ae. In. Press Release on April 2nd 2018."},{"key":"e_1_2_14_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3580"},{"key":"e_1_2_14_12_1","unstructured":"The US FDA:FDA Drug Safety Communication: FDA requires labeling changes for prescription opioid cough and cold medicines to limit their use to adults 18\u00a0years and older. March 22 2018 Available from:https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm590435.htm."},{"key":"e_1_2_14_13_1","unstructured":"European Medicine Agency:Codeine not to be used in children below 12 years for cough and cold. March 22 2018. Available from:http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl\u00a0=\u00a0pages\/medicines\/human\/referrals\/Codeine_containing_medicinal_products_for_the_treatment_of_cough_and_cold_in_paediatric_patients\/human_referral_prac_000039.jsp&mid\u00a0=\u00a0WC0b01ac05805c516f."},{"key":"e_1_2_14_14_1","unstructured":"Dear Healthcare Professionals Letter of rapid safety communication on Ranmark\u00ae on September 11th.2016. September 11th 2018. Available from:http:\/\/www.pmda.go.jp\/files\/000148439.pdf."},{"key":"e_1_2_14_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4392"},{"key":"e_1_2_14_16_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2710.2002.00430.x"},{"key":"e_1_2_14_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.287.19.2570"},{"key":"e_1_2_14_18_1","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.56.7428"},{"key":"e_1_2_14_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/70.1.41"},{"key":"e_1_2_14_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2005.07.004"},{"key":"e_1_2_14_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12197"},{"key":"e_1_2_14_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.EDE.0000081989.82616.7d"},{"key":"e_1_2_14_23_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.59.4.337"},{"key":"e_1_2_14_24_1","first-page":"30","article-title":"Hyperglycemia associated with the use of atypical antipsychotics","volume":"62","author":"Lindenmayer J","year":"2001","journal-title":"J Clin Psychiatry"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.4777","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.4777","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/pds.4777","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.4777","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T18:58:40Z","timestamp":1694285920000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.4777"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,3]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["10.1002\/pds.4777"],"URL":"https:\/\/doi.org\/10.1002\/pds.4777","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,3]]},"assertion":[{"value":"2018-11-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-02-28","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-04-03","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}